155 related articles for article (PubMed ID: 23098512)
1. Reconstructed adeno-associated virus with the extracellular domain of murine PD-1 induces antitumor immunity.
Elhag OA; Hu XJ; Wen-Ying Z; Li X; Yuan YZ; Deng LF; Liu DL; Liu YL; Hui G
Asian Pac J Cancer Prev; 2012; 13(8):4031-6. PubMed ID: 23098512
[TBL] [Abstract][Full Text] [Related]
2. Investigation on the effects of soluble programmed death-1 (sPD-1) enhancing anti-tumor immune response.
Yuan Y; He Y; Wang X; Zhang H; Li D; Feng Z; Zhang G
J Huazhong Univ Sci Technolog Med Sci; 2004; 24(6):531-4. PubMed ID: 15791831
[TBL] [Abstract][Full Text] [Related]
3. Regulating immunity and inhibiting tumor growth by the recombinant peptide sPD-1-CH50.
Qiu H; Liu S; Xie C; Long J; Feng Z
Anticancer Res; 2009 Dec; 29(12):5089-94. PubMed ID: 20044621
[TBL] [Abstract][Full Text] [Related]
4. [Soluble PD-1 can augment anti-tumor immunity induced by HSP70-peptide complex in tumor-bearing mice].
Wang XH; Zhang GM; He YF; Zhang H; Feng ZH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Nov; 20(6):655-8. PubMed ID: 15555427
[TBL] [Abstract][Full Text] [Related]
5. Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine.
He YF; Zhang GM; Wang XH; Zhang H; Yuan Y; Li D; Feng ZH
J Immunol; 2004 Oct; 173(8):4919-28. PubMed ID: 15470033
[TBL] [Abstract][Full Text] [Related]
6. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions.
Wu K; Kryczek I; Chen L; Zou W; Welling TH
Cancer Res; 2009 Oct; 69(20):8067-75. PubMed ID: 19826049
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
[TBL] [Abstract][Full Text] [Related]
8. Nanobubbles Containing sPD-1 and Ce6 Mediate Combination Immunotherapy and Suppress Hepatocellular Carcinoma in Mice.
Tan Y; Yang S; Ma Y; Li J; Xie Q; Liu C; Zhao Y
Int J Nanomedicine; 2021; 16():3241-3254. PubMed ID: 34007176
[TBL] [Abstract][Full Text] [Related]
9. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients.
Shi F; Shi M; Zeng Z; Qi RZ; Liu ZW; Zhang JY; Yang YP; Tien P; Wang FS
Int J Cancer; 2011 Feb; 128(4):887-96. PubMed ID: 20473887
[TBL] [Abstract][Full Text] [Related]
10. Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells.
Pen JJ; Keersmaecker BD; Heirman C; Corthals J; Liechtenstein T; Escors D; Thielemans K; Breckpot K
Gene Ther; 2014 Mar; 21(3):262-71. PubMed ID: 24401835
[TBL] [Abstract][Full Text] [Related]
11. Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8
Li J; Lee Y; Li Y; Jiang Y; Lu H; Zang W; Zhao X; Liu L; Chen Y; Tan H; Yang Z; Zhang MQ; Mak TW; Ni L; Dong C
Immunity; 2018 Apr; 48(4):773-786.e5. PubMed ID: 29625896
[TBL] [Abstract][Full Text] [Related]
12. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes.
Sawada Y; Yoshikawa T; Shimomura M; Iwama T; Endo I; Nakatsura T
Int J Oncol; 2015 Jan; 46(1):28-36. PubMed ID: 25354479
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
14. Blockade of B7-H1 with sPD-1 improves immunity against murine hepatocarcinoma.
He L; Zhang G; He Y; Zhu H; Zhang H; Feng Z
Anticancer Res; 2005; 25(5):3309-13. PubMed ID: 16101143
[TBL] [Abstract][Full Text] [Related]
15. [Eukaryotic expression and functional characterization of PD-1 extracellular domain].
He YF; Zhang GM; Wang XH; Zhang H; Yuan Y; Li D; Feng ZH
Sheng Wu Gong Cheng Xue Bao; 2004 Sep; 20(5):699-703. PubMed ID: 15973993
[TBL] [Abstract][Full Text] [Related]
16. Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo.
Xiao H; Huang B; Yuan Y; Li D; Han LF; Liu Y; Gong W; Wu FH; Zhang GM; Feng ZH
Clin Cancer Res; 2007 Mar; 13(6):1823-30. PubMed ID: 17325342
[TBL] [Abstract][Full Text] [Related]
17. Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein.
Pan Z; Di S; Shi B; Jiang H; Shi Z; Liu Y; Wang Y; Luo H; Yu M; Wu X; Li Z
Cancer Immunol Immunother; 2018 Oct; 67(10):1621-1634. PubMed ID: 30078052
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma.
Wang Y; Huang F; Cai H; Wu Y; He G; Tan WS
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1827-37. PubMed ID: 20213096
[TBL] [Abstract][Full Text] [Related]
19. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
20. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]